Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2421065 | 0.82 | LMNA (0.59) | SMN1; SMN2MAPK1MEN1KMT2ATDP1 | |
| SCHEMBL1201816 | 0.81 | LMNA (0.64) | LMNAACACB | |
| SCHEMBL1201984 | 0.80 | CA12 (0.51) | SMN1; SMN2KMT2ATDP1LMNA | |
| SCHEMBL28462964 | 0.80 | SMN1; SMN2 (0.64) | SMN1; SMN2MAPK1MEN1KMT2ATDP1 | |
| SCHEMBL8503477 | 0.80 | LMNA (0.57) | SMN1; SMN2MAPK1MEN1KMT2ATDP1 | |
| SCHEMBL8503491 | 0.80 | LMNA (0.57) | SMN1; SMN2MAPK1MEN1KMT2ATDP1 | |
| SCHEMBL27810662 | 0.79 | MAPT (0.47) | SMN1; SMN2MEN1KMT2ATDP1LMNA | |
| SCHEMBL2645672 | 0.79 | FFAR2 (0.47) | SMN1; SMN2MAPK1TDP1TP53LMNA | |
| SCHEMBL9258698 | 0.79 | RARB (0.56) | SMN1; SMN2MAPK1MEN1KMT2ATDP1 | |
| SCHEMBL27995630 | 0.79 | MMP8 (0.51) | SMN1; SMN2MEN1KMT2ALMNAMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2009036428-A2 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | SMN1; SMN2 1997/4885MAPK1 1846/4885MEN1 3767/4885 |
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | SMN1; SMN2 1997/4885MAPK1 1846/4885MEN1 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.